公开(公告)号：US12098352B2

公开(公告)日：2024-09-24

申请号：US16983850

申请日：2020-08-03

申请人： EMULATE, INC.

发明人： Janna Nawroth ,  Riccardo Barrile ,  David Conegliano ,  Remi Villenave ,  Carolina Lucchesi ,  Justin Nguyen ,  Antonio Varone ,  Catherine Karalis ,  Geraldine Hamilton

IPC分类号： C12M3/06 ,  B01L3/00 ,  C12N5/071 ,  C12N5/074

CPC分类号： C12M23/16 ,  B01L3/5027 ,  C12N5/0688 ,  C12N5/0696 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/155 ,  C12N2501/41 ,  C12N2502/1323 ,  C12N2502/27 ,  C12N2503/04 ,  C12N2506/02 ,  C12N2513/00 ,  G01N2800/12

摘要： An in vitro microfluidic “organ-on-chip” device is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a stem cell-based Lung-on-Chip is described. This in vitro microfluidic system can be used for modeling differentiation of cells on-chip into lung cells, e.g., a lung (Lung-On-Chip), bronchial (Airway-On-Chip; small-Airway-On-Chip), alveolar sac (Alveolar-On-Chip), etc., for use in modeling disease states of derived tissue, i.e. as healthy, pre-disease and diseased tissues. Additionally, stem cells under differentiation protocols for deriving (producing) differentiated lung cells off-chips may be seeded onto microfluidic devices at any desired point during the in vitro differentiation pathway for further differentiation on-chip or placed on-chip before, during or after terminal differentiation.

公开(公告)号：US20240288440A1

公开(公告)日：2024-08-29

申请号：US18247984

申请日：2021-10-06

申请人： Macfarlane Burnet Institute for Medical Research and Public Health

发明人： David Anderson ,  Heidi Drummer ,  Purnima Bhat ,  Huy Van

IPC分类号： G01N33/68 ,  A61K39/00 ,  A61K39/42 ,  C07K16/10 ,  G01N33/569

CPC分类号： G01N33/6854 ,  A61K39/42 ,  C07K16/1003 ,  G01N33/56983 ,  A61K2039/505 ,  C07K2317/35 ,  C07K2317/76 ,  G01N2333/165 ,  G01N2800/12 ,  G01N2800/52

摘要： The present application relates to infectious diseases, pathogenic organisms or pathogenic antigens, and the immune responses that are the body's first line of defense thereto. The application enables medical protocols and products inter alia for treating or preventing or limiting the dissemination of an infectious disease. Methods and compositions are disclosed which employ dIgA for assessing functional immune responses to a pathogen, and in prophylactic or therapeutic compositions. In particular embodiments, the methods and compositions enhance the armamentarium for those charged with managing infectious diseases and populations exposed to highly transmissible and potentially debilitating or fatal pathogens such as those causing epidemics. One particular infectious disease is COVID-19 caused by the virus SARS-COV-2.

公开(公告)号：US20240148274A1

公开(公告)日：2024-05-09

申请号：US18284273

申请日：2022-03-31

申请人： Zeteo Tech, Inc.

发明人： Dapeng CHEN ,  Wayne A. BRYDEN ,  Michael MCLOUGHLIN

IPC分类号： A61B5/097 ,  A61B5/00 ,  A61B5/083 ,  A61M16/08 ,  G01N1/40 ,  G01N33/68

CPC分类号： A61B5/097 ,  A61B5/0836 ,  A61B5/7203 ,  A61M16/0808 ,  G01N1/4044 ,  G01N33/6851 ,  G01N33/6893 ,  A61B2560/0431 ,  G01N2800/12 ,  G01N2800/26

摘要： Methods and devices for capturing and analyzing aerosolized particles in exhaled breath characteristic of a respiratory disease to enable rapid, low-cost point of care assays for several diseases including respiratory tract diseases such as COVID-19 are disclosed. The disclosed methods and systems selectively capture aerosolized particles using a packed bed column. The captured particles are then eluted using solvents and analyzed using analytical devices including MALDI-TOFMS.

公开(公告)号：US20240142467A1

公开(公告)日：2024-05-02

申请号：US18474419

申请日：2023-09-26

申请人： Boehringer Ingelheim International GmbH

发明人： Christian Benedikt Otto HESSLINGER ,  Franziska Elena HERRMANN ,  Yi LIU ,  Peter NICKOLAUS

IPC分类号： G01N33/68 ,  C07D409/14

CPC分类号： G01N33/6893 ,  C07D409/14 ,  G01N2800/12 ,  G01N2800/52

摘要： The PDE4-inhibitor of formula A′




for use in a method for the treatment of a progressive fibrosing interstitial lung disease (PF-ILD), preferably IPF, in a patient comprising the following steps:



a) measuring or having measured the concentration, expression level or activity of one or more biomarkers selected from the group consisting of Krebs von den Lungen protein (KL-6), Pulmonary Surfactant Protein D (SP-D), Matrilysin (MMP7), CA-125 (also named MUC-16), CA19-9, E-selectin, sICAM-1, Stromelysin (MMP3), osteopontin (OPN), connective tissue growth factor (CTGF), Cartilage oligomeric matrix protein (COMP), prostasin, von-Willebrand-Faktor (vWF), and C-reactive protein (CRP) in the serum or plasma of a blood sample obtained from said patient,
b) comparing or having compared the concentration, expression level or activity of the one or more biomarkers as listed in step a) in said patient's blood serum or blood plasma sample to a reference concentration, expression level or activity of the respective one or more biomarkers,
c) determining or having determined that the concentration, expression level or activity of the respective one or more biomarkers as listed in step a) is modified compared to a respective reference concentration, expression or activity of that respective one or more biomarker,
d) administering to said patient a therapeutically efficient amount of the PDE4-inhibitor of formula A′.

公开(公告)号：US20230408531A1

公开(公告)日：2023-12-21

申请号：US17929831

申请日：2022-09-06

申请人： Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences

发明人： Jing WANG ,  Tiantian ZHANG ,  Youliang SUN ,  Xianmei QI

IPC分类号： G01N33/68 ,  C12Q1/32

CPC分类号： G01N33/6893 ,  C12Q1/32 ,  G01N2800/12 ,  C12Q2600/158 ,  A01K67/0276

摘要： The present disclosure provides use of malic enzyme 2 (ME2) in preparation of a diagnostic reagent or a medicament for silicosis or pulmonary fibrosis-related diseases, and belongs to the technical fields of medical treatment and medicine. Research results of the present disclosure show that ME2 knockout significantly alleviates inflammatory response and fibrotic lesions in mice with silicosis. Based on the above research results, the present disclosure provides use of ME2 in treatment of pulmonary inflammatory responses and pulmonary fibrotic lesions of silicosis or pulmonary fibrosis-related diseases. Expression of ME2 is inhibited to alleviate the inflammatory response and fibrotic lesions of the silicosis, providing support for exploring a targeted drug for treating pulmonary inflammatory responses and pulmonary fibrosis of silicosis or pulmonary fibrosis-related diseases.

公开(公告)号：US11781980B2

公开(公告)日：2023-10-10

申请号：US16754009

申请日：2018-10-05

申请人： SIME DIAGNOSTICS LTD.

发明人： Peter Schousboe ,  Henrik Verder

IPC分类号： G01N33/92 ,  G01N21/3577 ,  G01N1/40 ,  G01N33/487

CPC分类号： G01N21/3577 ,  G01N1/4077 ,  G01N33/487 ,  G01N33/92 ,  G01N2001/4083 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2800/12

摘要： The present invention relates to methods for diagnosing Respiratory Distress Syndrome of newborn.

公开(公告)号：US20230304993A1

公开(公告)日：2023-09-28

申请号：US18048759

申请日：2022-10-21

申请人： The Scripps Research Institute ,  The Board of trustees of the Leland Stanford Junior University

发明人： Peter Kuhn ,  Anders Carlsson ,  Anand Kolatkar ,  Sanjiv Sam Gambhir ,  Viswam S. Nair

IPC分类号： G01N33/50 ,  A61K51/04 ,  A61K49/00

CPC分类号： G01N33/5026 ,  A61K51/0491 ,  A61K49/00 ,  G01N33/5005 ,  G01N2800/12 ,  G01N2800/7028

摘要： The present invention provides methods for diagnosing lung cancer in a subject comprising (a) generating circulating tumor cell (CTC) data from a blood sample obtained from the subject based on a direct analysis comprising immunofluorescent staining and morphological characteristics of nucleated cells in the sample, wherein CTCs are identified in context of surrounding nucleated cells based on a combination of the immunofluorescent staining and morphological characteristics; (b) obtaining clinical data for the subject; (c) combining the CTC data with the clinical data to diagnose lung cancer in the subject.

公开(公告)号：US11726098B2

公开(公告)日：2023-08-15

申请号：US16726429

申请日：2019-12-24

申请人： UNIVERSITY OF PRETORIA

发明人： Jan Adrianus Verschoor ,  Carl Baumeister

IPC分类号： G01N33/543 ,  G01N33/569 ,  G01N33/68

CPC分类号： G01N33/6854 ,  G01N33/5432 ,  G01N33/5438 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2469/20 ,  G01N2800/12

摘要： Immobilising isolated mycolic acid antigens of tuberculous mycobacterial origin or a synthetic analogue thereof on a screen-printed electrode by binding of the antigens to a self-assembled monolayer comprising a thiolated hydrophobic substance to produce immobilized mycolic acids antigens in the form of a mycolic acid antigen-containing self-assembled monolayer coating on a surface of the electrode.

公开(公告)号：US20230236207A1

公开(公告)日：2023-07-27

申请号：US18158768

申请日：2023-01-24

申请人： University of Rochester

发明人： Irfan Rahman ,  Matthew McGraw

IPC分类号： G01N33/68 ,  G01N33/92

CPC分类号： G01N33/6893 ,  G01N33/92 ,  G01N2800/12

摘要： The present invention generally relates to novel biomarkers and their methods of use for identifying and treating e-cigarette, or vaping, product use-associated lung injury (EVALI).

公开(公告)号：US20190194725A1

公开(公告)日：2019-06-27

申请号：US16079450

申请日：2017-02-24

申请人： UCL BUSINESS PLC

发明人： Mahdad NOURSADEGHI ,  Jennifer ROE ,  Adrian MARTINEAU

IPC分类号： C12Q1/689 ,  G01N33/68

CPC分类号： C12Q1/689 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/12 ,  G01N2800/26 ,  G01N2800/56

摘要： The present invention relates to a method of determining the presence or absence of active tuberculosis in a sample, in particular, comprising determining the levels of one or more biomarkers selected from basic leucine zipper transcription factor ATF-like 2 (BATF2), cluster of differentiation 177 (CD177), haptoglobin (HP), immunoglobulin J chain (IGJ) and galectin 10 (CLC), in said sample. Uses of biomarkers of the invention and kits for performing the method of the invention are also described.